Filing Details
- Accession Number:
- 0001193125-17-231357
- Form Type:
- 13D Filing
- Publication Date:
- 2017-07-19 17:08:33
- Filed By:
- Goldman Sachs Group Inc
- Company:
- Goldman Sachs Group Inc (NYSE:GS)
- Filing Date:
- 2017-07-19
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Each of the persons identified on Appendix A. | 0 | 18,701,019 | 4.79% | |||
indicated) Names of Reporting Persons indicated) ---------------------------- ---------------- ---------------------------- ------------------ Paul R. Aaron Tavis Cannell UK Ireland Fadi Abuali Canada Kuwait Valentino D. Carlotti Charles F. Adams Michael J. Carr Nicole Vijay Agnew Canada David E. Casner Gregory A. Agran Kenneth Gerard Castelino India Raanan A. Agus Donald J. Casturo Philip S. Armstrong UK Christian Channell UK Aaron M. Arth Sonjoy Chatterjee India Armen A. Avanessians R. Martin Chavez Dean C. Backer Alex S. Chi Charles Baillie David Chou UK Andrew J. Bagley UK Gary W. Chropuvka Vivek J. Bantwal Thalia Chryssikou Greece Jennifer A. Barbetta Massimiliano Ciardi Italy Steven K. Barg Kent A. Clark Canada USA Thomas J. Barrett III Alan M. Cohen Jonathan Barry Darren W. Cohen Steven M. Barry Stephanie E. Cohen Stacy Bash-Polley Colin Coleman South Africa Gareth W. Bater UK Denis P. Coleman III Jonathan Andrew Bagot Kathleen A. Connolly Bayliss UK Thomas G. Connolly Ireland USA Gerard M. Beatty Karen R. Cook UK Deborah R. Beckmann Edith W. Cooper Jonathan A. Beinner Kenneth W. Coquillette Heather Bellini Richard N. Cormack UK Tracey E. Benford David Coulson USA UK Philip R. Berlinski Belgium USA James V. Covello Frances R. Bermanzohn Christopher A. Crampton Robert A. Berry UK USA Jeffrey R. Currie Avanish R. Bhavsar Michael D. Daffey Australia Lloyd C. Blankfein Canute H. Dalmasse Vivek Bohra Anne Marie B. Darling Stefan R. Bollinger Switzerland David H. Dase Brian W. Bolster Michael J. Daum Shane M. Bolton UK Jennifer L. Davis Robert D. Boroujerdi Francois-Xavier de Mallmann France Switzerland Jill A. Borst Daniel L. Dees William C. Bousquette, Jr. Mark F. Dehnert Sally A. Boyle UK Massimo Della Ragione Italy Michael J. Brandmeyer Sara V. Devereux Jason H. Brauth Olaf Diaz-Pintado Spain Clarence K. Brenan Joseph P. DiSabato Samuel S. Britton Michele I. Docharty Craig W. Broderick Thomas M. Dowling Michael Bruun Denmark Robert Drake-Brockman UK Steven M. Bunson Iain N. Drayton UK Robert A. Camacho Alessandro Dusi Italy Philippe L. Camu Belgium Isabelle Ealet France -3- ITEM | ||||||
indicated) Names of Reporting Persons indicated) ---------------------------- ---------------- ---------------------------- ---------------- Kenneth M. Eberts III Andrew M. Gordon David P. Eisman Sarah J. Gray UK Charalampos Eliades Greece Michael J. Graziano James Ellery UK Nishi Grose UK Kathleen G. Elsesser Bradley J. Gross UK USA Edward A. Emerson Argentina UK Peter Gross James P. Esposito Anthony Gutman UK USA Michael P. Esposito Carey Halio Carl Faker France Lebanon Elizabeth M. Hammack Elizabeth C. Fascitelli Joanne Hannaford UK Patrick J. Fels Jan Hatzius Germany Benjamin W. Ferguson Brian Michael Haufrect Carlos Fernandez-Aller Spain Peter Hermann Denmark Jonathan H. Fine UK USA Edouard Hervey France Wolfgang Fink Germany Matthias Hieber Austria Samuel W. Finkelstein Charles P. Himmelberg Peter E. Finn Amanda S. Hindlian David A. Fishman Martin Hintze Germany Colleen A. Foster Kenneth L. Hirsch David A. Fox Kenneth W. Hitchner Sheara J. Fredman Simon N. Holden UK Christopher G. French UK Dane E. Holmes David A. Friedland Ning Hong China Richard A. Friedman Sean C. Hoover Johannes P. Fritze Germany USA Harold P. Hope III Andrew John Fry Australia Ericka T. Horan Dino Fusco Shin Horie Japan Jacques Gabillon France Russell W. Horwitz Charlie H. Gailliot James P. Houghton UK Sean J. Gallagher Erdit F. Hoxha Albania UK Gonzalo R. Garcia Chile Pierre Hudry France James R. Garman UK Kathleen Hughes Ireland USA M. Huntley Garriott, Jr. Ming Yunn Stephanie Hui UK Hong Kong Francesco U. Garzarelli Italy Irfan S. Hussain Pakistan Gabriel Elliot Gelman Russell E. Hutchinson Canada USA Matthew R. Gibson Hidehiro Imatsu Japan Jeffrey M. Gido Timothy J. Ingrassia Gary T. Giglio Omer Ismail USA Pakistan Nick V. Giovanni William L. Jacob III Joshua Glassman Christian W. Johnston Australia John L. Glover III Andrew J. Jonas Justin G. Gmelich Adrian M. Jones Ireland Richard J. Gnodde Ireland South Eric S. Jordan Africa Roy R. Joseph Guyana Cyril J. Goddeeris Canada Andrew J. Kaiser Jeffrey B. Goldenberg Etsuko Kanayama Japan Alexander S. Golten UK Vijay M. Karnani India Court E. Golumbic Alan S. Kava Parameswaran Gopikrishnan India Geraldine Keefe UK Spain -4- ITEM | ||||||
indicated) Names of Reporting Persons indicated) ---------------------------- ---------------- ---------------------------- ---------------- Andre Helmut Kelleners Germany Paget MacColl Kevin G. Kelly Paula B. Madoff Christopher Keogh John G. Madsen Aasem G. Khalil Raja Mahajan Tammy A. Kiely John A. Mahoney John J. Kim Puneet Malhi UK Robert C. King, Jr. Raghav Maliah India Simon J. Kingsbury UK John V. Mallory Hideki Kinuhata Japan Richard M. Manley UK Shigeki Kiritani Japan Clifton C. Marriott USA UK Marie Louise Kirk Denmark Michael C. J. Marsh UK Maxim B. Klimov Ukraine Elizabeth Gregory Martin Edward C. Knight UK Sarah Marie Martin Michael E. Koester Alison J. Mass Kathryn A. Koch US UK Robert A. Mass J. Christopher A. Kojima Canada USA Jason L. Mathews Adam M. Korn Kathy M. Matsui David J. Kostin Alexander Mayer Germany Jorg H. Kukies Germany John J. McCabe Meena K. Lakdawala Matthew B. McClure UK Tuan Lam Dermot W. McDonogh Ireland Eric S. Lane Brendan Michael McGovern David W. Lang John J. McGuire, Jr. Nyron Z. Latif Sean T. McHugh Bruce M. Larson John W. McMahon Hugh J. Lawson James A. McNamara Scott L. Lebovitz Richard P. McNeil Jamaica USA Brian J. Lee Celine Mechain France George C. Lee Avinash Mehrotra Gregory P. Lee Ali S. Melli Saint Kitts and Ronald Lee Nevis David A. Lehman Xavier C. Menguy France Todd W. Leland David D. Miller Laurent Lellouche France Milton R. Millman III Gregg R. Lemkau Jung Min Gavin J. Leo-Rhynie USA Jamaica Christina P. Minnis Deborah R. Leone Kayhan Mirza Canada Eugene H. Leouzon France Masanori Mochida Japan John R. Levene UK Timothy H. Moe Ireland Brian T. Levine Joseph Montesano Tianqing Li Hong Kong Ricardo Mora Gwen R. Libstag Sam Alexander Morgan UK Dirk L. Lievens Belgium Thomas C. Morrow Ryan D. Limaye Edward Gary Morse, Jr. Luca M. Lombardi Italy Sharmin Mossavar-Rahmani UK Victor M. Lopez-Balboa Heather Louise Mulahasani Kyriacos Loupis Cyprus USA Majedabadi Kohne UK David B. Ludwig Eric D. Muller Peter J. Lyon Takashi Murata Japan -5- ITEM | ||||||
indicated) Names of Reporting Persons indicated) ----------------------------- ---------------- ---------------------------- ---------------- Marc O. Nachmann John F. W. Rogers Ezra Nahum France USA Scott A. Romanoff Amol S. Naik India USA Johannes Rombouts The Netherlands Jyothsna Natauri Michael E. Ronen Germany Israel Una M. Neary Simon A. Rothery Australia Jeffrey P. Nedelman Jason T. Rowe Dimitrios Nikolakopoulos Australia UK Jami Rubin Greece David T. Rusoff Fergal J. O Driscoll Ireland Peter C. Russell Gregory G. Olafson Canada Paul M. Russo Brett A. Olsher UK USA Colin J. Ryan Ireland Jernej Omahen Slovenia Ankur A. Sahu India Timothy J. O Neill Mahesh Saireddy Lisa Opoku Pablo J. Salame Peter C. Oppenheimer UK Julian Salisbury UK Gerald B. Ouderkirk III Thierry Sancier France Michael Martin Paese Luke A. Sarsfield III Gregory K. Palm Adam H. Savarese Konstantinos N. Pantazopoulos Greece Jason M. Savarese James R. Paradise UK John R. Sawtell UK Paul Gray Parker Susan J. Scher Francesco Pascuzzi Italy Stephen M. Scherr Anthony W. Pasquariello Clare R. Scherrer Sheila H. Patel Joshua S. Schiffrin Nirubhan Pathmanabhan UK Jeffrey W. Schroeder David B. Philip Harvey M. Schwartz Nicholas W. Phillips UK David A. Schwimmer Hugh R. Pill UK Stephen B. Scobie UK Ellen R. Porges John A. Sebastian Kim-Thu Posnett Stacy D. Selig Dmitri Potishko Australia Gaurav Seth India Alexander E. Potter Kunal K. Shah UK Gilberto Pozzi Italy Tejas A. Shah Macario Prieto Spain Konstantin A. Shakhnovich Robert Pulford UK Heather K. Shemilt Canada Xiao Qin UK Michael H. Siegel John J. Rafter Ireland Richard L. Siewert, Jr. Sumit Rajpal Suhail A. Sikhtian Ganesh Ramani India Jason E. Silvers Richard N. Ramsden UK Nicholas Sims Australia Marko John Ratesic Gavin Simms UK Andrew K. Rennie Australia UK Michael L. Simpson Lawrence J. Restieri, Jr. Kristin O. Smith James H. Reynolds France Marshall Smith Kate D. Richdale UK Sarah E. Smith UK Michael J. Richman David M. Solomon Francois J. Rigou France Mark R. Sorrell UK Michael Rimland Christoph W. Stanger Austria Scott M. Rofey Esta E. Stecher -6- ITEM | ||||||
indicated) Names of Reporting Persons indicated) ---------------------------- ---------------- ---------------------------- ---------------- Laurence Stein South Africa USA Toshihiko Umetani Japan Kevin M. Sterling Peter van der Goes, Jr. John D. Storey Australia Mark A. Van Wyk Patrick M. Street UK Damien R. Vanderwilt Australia UK Steven H. Strongin Jonathan R. Vanica Joseph Struzziery III Ashok Varadhan Umesh Subramanian India Christoph Vedral Germany Ram K. Sundaram India Andrea Vella Italy Li Hui Suo China Philip J. Venables UK USA Damian E. Sutcliffe UK USA Rajesh Venkataramani Robert J. Sweeney Simone Verri Italy Michael S. Swell Matthew P. Verrochi Joseph D. Swift Jeffrey L. Verschleiser Aurora J. Swithenbank USA UK Robin A. Vince UK USA Gene T. Sykes Alejandro Vollbrechthausen Mexico Christopher W. Taendler John E. Waldron Harit Talwar Simon R. Watson UK Jeremy Taylor Peter A. Weidman Megan M. Taylor Owen O. West Richard J. Taylor UK Ronnie A. Wexler Thomas D. Teles Elisha Wiesel Pawan Tewari David D. Wildermuth Ryan J. Thall John S. Willian David S. Thomas Andrew F. Wilson New Zealand Ben W. Thorpe UK Andrew E. Wolff Oliver Thym Germany Neil Edward Wolitzer Andrew R. Tilton Denise A. Wyllie UK Joseph K. Todd Yoshihiko Yano Japan Klaus B. Toft Denmark Shinichi Yokote Japan Hiroyuki Tomokiyo Japan W. Thomas York, Jr. Thomas Tormey Wassim G. Younan Lebanon UK Frederick Towfigh Han Song Zhu China Padideh Nora Trojanow USA UK Adam J. Zotkow Kenro Tsutsumi Japan Eiji Ueda Japan -7- This Amendment No |
Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
File No. 005-56295
-----------------
SCHEDULE 13D/A
(Rule 13d-101)
Amendment No. 94
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
The Goldman Sachs Group, Inc.
(Name of Issuer)
Common Stock, par value $.01 per share
(Title of Class of Securities)
38141G 10 4
(CUSIP Number)
Kenneth L. Josselyn
The Goldman Sachs Group, Inc.
200 West Street
New York, New York 10282
Telephone: (212) 902-1000
(Name, Address and Telephone Number of Persons Authorized to
Receive Notices and Communications)
July 3, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [_].
(Continued on following pages)
Appendix A
-3-
This Amendment No. 94 to a Statement on Schedule 13D amends and
restates in its entirety such Schedule 13D (as so amended and restated, this
"Schedule"). This Amendment No. 94 is being filed primarily because the number
of shares of Common Stock (as defined in Item 1 below) beneficially owned by
Covered Persons (as defined in Item 2 below) has decreased by an amount in
excess of one percent of the total number of shares of Common Stock outstanding.
ITEM 1. Security and Issuer
This Schedule relates to the Common Stock, par value $.01 per share
(the "Common Stock"), of The Goldman Sachs Group, Inc. ("GS Inc."), a Delaware
corporation. The address of the principal executive offices of GS Inc. is 200
West Street, New York, New York 10282.
ITEM 2. Identity and Background
(a), (b), (c), (f) The cover page to this Schedule and Appendix A
hereto contain the names of the individuals ("Covered Persons") who are parties
to an Amended and Restated Shareholders' Agreement, originally dated as of
May 7, 1999 and amended and restated effective as of January 15, 2015 (as
amended from time to time, the "Shareholders' Agreement"). This filing is being
made on behalf of all of the Covered Persons, and their agreement that this
filing may be so made is contained in the Shareholders' Agreement.
Appendix A hereto also provides the citizenship of each Covered
Person. Each Covered Person is a current or former Participating Managing
Director (as defined in Item 6 below) of GS Inc. or one of its affiliates. GS
Inc. is a global investment banking, securities and investment management firm.
The business address of each Covered Person for purposes of this Schedule is
200 West Street, New York, New York 10282.
(d), (e) During the last five years no Covered Person has been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or has been a party to a civil proceeding or a judicial or
administrative body of competent jurisdiction resulting in such Covered Person
being subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws.
ITEM 3. Source and Amount of Funds or Other Consideration
The Covered Persons have acquired and will acquire shares of Common
Stock in the following manners: (i) the former profit participating limited
partners active in the business of The Goldman Sachs Group, L.P. ("Group L.P.")
(the "IPO PMDs") acquired certain shares of Common Stock in exchange for their
interests in Group L.P. and certain of its affiliates and investee
corporations; (ii) the former owners (the "Acquisition Covered Persons") of
Hull and Associates, L.L.C. ("Hull") and Goldman Sachs & Partners Australia
Group Holdings Pty Ltd ("GS&PA") acquired certain shares of Common Stock in
exchange for their interests in Hull and GS&PA, respectively; and (iii) certain
Covered Persons have acquired and will acquire beneficial ownership of certain
shares of Common Stock in connection with GS Inc.'s initial public offering
and/or pursuant to GS Inc.'s employee compensation, benefit or similar plans.
Covered Persons may from time to time acquire shares of Common Stock
for investment purposes. Such Common Stock may be acquired with personal funds
of or funds borrowed by such Covered Person.
ITEM 4. Purpose of Transactions
The Covered Persons, other than the Acquisition Covered Persons,
acquired certain shares of Common Stock in connection with the succession of GS
Inc. to the business of Group L.P. and GS Inc.'s initial public offering and/or
through certain employee compensation, benefit or similar plans of GS Inc. The
Acquisition Covered Persons acquired certain shares of Common Stock in
connection with the acquisition by GS Inc. of Hull or GS&PA, as applicable, and
through certain employee compensation, benefit or similar plans of GS Inc.
Covered Persons may from time to time acquire shares of Common Stock
for investment purposes. Except as described herein and in Annex A and except
for the acquisition by Covered Persons of Common Stock
-8-
pursuant to employee compensation, benefit or similar plans of GS Inc. in the
future or as described above, none of the Covered Persons has any plans or
proposals which relate to or would result in the acquisition of additional
Common Stock by them or any of the other events described in Item 4(a) through
4(j).
Each Covered Person is expected to evaluate on an ongoing basis GS
Inc.'s financial condition and prospects and his or her interests in and with
respect to GS Inc. Accordingly, each Covered Person may change his or her plans
and intentions at any time and from time to time. In particular, each Covered
Person may at any time and from time to time acquire or dispose of shares of
Common Stock.
ITEM 5. Interest in Securities of the Issuer
(a) Rows (11) and (13) of the cover page to this Schedule and Appendix
A are hereby incorporated by reference. Each Covered Person hereby disclaims
beneficial ownership of any shares of Common Stock held by any other Covered
Person. Except as described in Annex B, none of the shares of Common Stock
reported in rows (11) and (13) of the cover page to this Schedule and Appendix
A are shares as to which there is a right to acquire exercisable within 60 days.
(b) Rows (7) through (10) of the cover page to this Schedule set forth
for each Covered Person: the percentage range of Voting Shares, Shared
Ownership Shares, Sixty Day Shares and Other Shares (each as defined on the
cover page hereof) as to which there is sole power to vote or direct the vote
or to dispose or direct the disposition or shared power to vote or direct the
vote or to dispose or direct the disposition. The power to vote Voting Shares
by Covered Persons is shared with each other Covered Person, as described below
in response to Item 6. Each Covered Person hereby disclaims beneficial
ownership of any shares of Common Stock held by any other Covered Person.
(c) Except as described in Annex C or previously reported on Schedule
13D, no Covered Person has effected any transactions in Common Stock in the 60
days preceding July 3, 2017.
(d) Not Applicable.
(e) As of July 3, 2017, the Covered Persons beneficially owned less
than 5% of the outstanding Common Stock.
ITEM 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
Each Covered Person listed on the cover page to this Schedule and
Appendix A hereto is a party to the Shareholders' Agreement. The Shareholders'
Agreement and forms of the Counterparts to the Shareholders' Agreement are
filed as Exhibits to this Schedule, and the following summary of the terms of
the Shareholders' Agreement is qualified in its entirety by reference thereto.
References to the "board of directors" are to the board of directors of GS Inc.
The Covered Persons under the Shareholders' Agreement include all
Managing Directors of GS Inc. who participate in the GS Inc. Partner
Compensation Plan or Restricted Partner Compensation Plan (each as defined in
the Shareholders' Agreement) or any other employee benefit plan specified by
the Shareholders' Committee described below under "Information Regarding the
Shareholders' Committee" (the "Participating Managing Directors").
The "Voting Shares" include all of the shares of Common Stock of which
a Covered Person (or, in approved cases, his or her spouse or domestic partner)
is the sole beneficial owner (excluding shares of Common Stock held by the
trust underlying The Goldman Sachs 401(k) Plan). The interest of a spouse or
domestic partner in a joint account, an economic interest of GS Inc. as
pledgee, and the interest of certain persons in approved estate planning
vehicles will be disregarded for the purposes of determining whether a Covered
Person is the sole beneficial owner of shares of Common Stock.
TRANSFER RESTRICTIONS
Each Covered Person has agreed in the Shareholders' Agreement, among
other things, to retain sole beneficial ownership of a number of shares of
Common Stock at least equal to 25% of such Covered Person's Covered Shares (as
defined below); provided, that with respect to 2009 year-end equity awards
granted in
-9-
accordance with the equity deferral table approved by the board of directors or
its Compensation Committee, such number shall equal 30% of the Covered Shares
relating thereto (the "General Transfer Restrictions"). Effective January 15,
2015 (the "Effective Date"), in connection with GS Inc.'s implementation of
stock ownership guidelines (the "Guidelines") for its senior executive
officers, the transfer restrictions in the Shareholders' Agreement applicable
to certain senior officers designated by the Shareholders' Committee (the
"Special Transfer Restrictions" and, together with the General Transfer
Restrictions, the "Transfer Restrictions") were amended to require such
officers to retain sole beneficial ownership of a number of shares of Common
Stock at least equal to 50% of the increase (or, if such Covered Person is then
the chief executive officer of GS Inc., 75% of the increase) in Covered Shares
received by or delivered to such Covered Person following the Effective Date.
The prior Special Transfer Restrictions, which required each senior officer to
retain 75% of his or her Covered Shares, will continue to apply to deliveries
made prior to the Effective Date. The Guidelines require that the Corporation's
chief executive officer hold shares of common stock equal to 10 times his or
her base salary and each other senior executive officer hold shares of common
stock equal to 6 times his or her base salary. The same shares may be used to
satisfy the Guidelines, the Special Transfer Restrictions and the General
Transfer Restrictions. The Transfer Restrictions applicable to a Covered Person
terminate upon the death of the Covered Person. Shares beneficially owned by a
Covered Person through certain approved estate planning vehicles established by
Covered Persons or, as applicable, by the Covered Person's spouse or domestic
partner are generally deemed to count toward the satisfaction of the Transfer
Restrictions.
For these purposes, "Covered Shares," with respect to a Covered
Person, will be recalculated each time the Covered Person receives Common Stock
underlying an award of restricted stock units, exercises a stock option (not
including, in each case, awards in connection with GS Inc.'s initial public
offering) or receives an award of restricted stock. The calculation of Covered
Shares will include the gross number of shares underlying such restricted stock
units or stock options or the gross number of shares of restricted stock, in
each case less (i) a number of shares determined by reference to tax rates
specified by the Shareholders' Committee and (ii) the number of shares
necessary to cover the option exercise price, if applicable (all as calculated
pursuant to a formula set out in the Shareholders' Agreement). The calculation
of Covered Shares will only take into account awards that occurred after the
Covered Person became a Participating Managing Director. The Shareholders' Committee has the power to determine, and has determined from time to time in
particular situations, whether restricted stock or shares of Common Stock
delivered pursuant to restricted stock units or stock options are deemed
"Covered Shares."
WAIVERS
The Shareholders' Committee has the power to waive, and has waived,
the Transfer Restrictions from time to time to permit Covered Persons to
transfer Common Stock in particular situations (such as transfers to family
members, partnerships or trusts), but not generally. The Shareholders' Committee also has the power to waive the Transfer Restriction to permit
Covered Persons to: participate as sellers in underwritten public offerings of,
and stock repurchase programs and tender and exchange offers by GS Inc. for,
Common Stock; transfer Common Stock to charities, including charitable
foundations; and transfer Common Stock held in employee benefit plans. Taking
into account the Shareholders' Committee's waivers and determinations regarding
Covered Shares to date, 7,479,081 shares of Common Stock are subject to the
Transfer Restrictions as of July 3, 2017.
In the case of a third-party tender or exchange offer, the Transfer
Restrictions may be waived or terminated: if the board of directors is
recommending acceptance or is not making any recommendation with respect to
acceptance of the tender or exchange offer, by a majority of the outstanding
Covered Shares; or if the board of directors is recommending rejection of the
tender or exchange offer, by 66 2/3% of the outstanding Covered Shares.
In the case of a tender or exchange offer by GS Inc., a majority of
the outstanding Covered Shares may also waive or terminate the Transfer
Restrictions.
VOTING
Prior to any vote of the shareholders of GS Inc., the Shareholders' Agreement requires a separate, preliminary vote of substantially all Voting
Shares on each matter upon which a vote of the shareholders is proposed to be
taken (the "Preliminary Vote"). Each Voting Share will be voted in accordance
with the majority of the votes cast by the Voting Shares in the Preliminary
Vote. In elections of directors, each Voting Share will be voted in
-10-
favor of the election of those persons, equal in number to the number of such
positions to be filled, receiving the highest numbers of votes cast by the
Voting Shares in the Preliminary Vote.
OTHER RESTRICTIONS
The Shareholders' Agreement also prohibits Covered Persons from
engaging in certain activities relating to any securities of GS Inc. with any
person who is not a Covered Person or a director, officer or employee of GS
Inc. ("Restricted Persons"). Among other things, a Covered Person may not:
participate in a proxy solicitation to or with a Restricted Person; deposit any
shares of Common Stock in a voting trust or subject any shares of Common Stock
to any voting agreement or arrangement that includes any Restricted Person;
form, join or in any way participate in a "group" with any Restricted Person;
or together with any Restricted Person, propose certain transactions with GS
Inc. or seek the removal of any directors of GS Inc. or any change in the
composition of the board of directors.
TERM, AMENDMENT AND CONTINUATION
The Shareholders' Agreement is to continue in effect until the earlier
of January 1, 2050 and the time it is terminated by the vote of 66 2/3% of the
outstanding Covered Shares. The Shareholders' Agreement may generally be
amended at any time by a majority of the outstanding Covered Shares.
Unless otherwise terminated, in the event of any transaction in which
a third party succeeds to the business of GS Inc. and in which Covered Persons
hold securities of the third party, the Shareholders' Agreement will remain in
full force and effect as to the securities of the third party, and the third
party shall succeed to the rights and obligations of GS Inc. under the
Shareholders' Agreement.
INFORMATION REGARDING THE SHAREHOLDERS' COMMITTEE
The Shareholders' Committee constituted pursuant to the Shareholders' Agreement (the "Shareholders' Committee") shall at any time consist of each of
those individuals who are both Covered Persons and members of the board of
directors and who agree to serve as members of the Shareholders' Committee. If
there are less than three individuals who are both Covered Persons and members
of the board of directors and who agree to serve as members of the
Shareholders' Committee, the Shareholders' Committee shall consist of each such
individual plus such additional individuals who are Covered Persons and who are
selected pursuant to procedures established by the Shareholders' Committee as
shall assure a Shareholders' Committee of not less than three members who are
Covered Persons. Currently, Lloyd C. Blankfein, Harvey M. Schwartz and David M.
Solomon are the members of the Shareholders' Committee.
EMPLOYEE BENEFIT PLAN TRANSFER RESTRICTIONS
Shares of Common Stock delivered to Covered Persons pursuant to
certain GS Inc. employee compensation plans and arrangements are subject to
restrictions on transfer. These restrictions lapse at various times depending
on the terms of the grant or award.
REGISTRATION RIGHTS INSTRUMENT FOR FORMER EMPLOYEE MANAGING DIRECTORS
In connection with the sale by certain Covered Persons (the "Former
Employee Managing Directors") of shares of Common Stock acquired from GS Inc.
pursuant to the terms of restricted stock units, GS Inc. entered into a
Supplemental Registration Rights Instrument, dated as of June 19, 2000 (the
"EMD Supplement"), which supplements the Registration Rights Instrument, dated
as of December 10, 1999 (the "Registration Rights Instrument"). The following
is a description of the Registration Rights Instrument, as supplemented by the
EMD Supplement. The Registration Rights Instrument and the EMD Supplement are
filed as Exhibits to this Schedule, and the following summary of these
agreements is qualified in its entirety by reference thereto.
Pursuant to the Registration Rights Instrument and the EMD Supplement,
GS Inc. has agreed to pay all of the fees and expenses relating to the
registered offering of shares of Common Stock held by the Former Employee
Managing Directors, other than any agency fees and commissions or underwriting
commissions or discounts or any transfer taxes incurred by the Former Employee
Managing Directors in connection with the sales. GS Inc. also has
-11-
agreed to indemnify the Former Employee Managing Directors against certain
liabilities, including those arising under the Securities Act.
DERIVATIVE INSTRUMENTS
Certain Covered Persons have entered into derivative transactions with
regard to shares of Common Stock as described in Annex D.
-12-
Material to be Filed as Exhibits
Exhibit Description
------- ----------------------------------------------------------------------
A. Registration Rights Instrument, dated as of December 10, 1999
(incorporated by reference to Exhibit G to Amendment No. 1 to the
Initial Schedule 13D, filed December 17, 1999 (File No. 005-56295)).
B. Form of Counterpart to Shareholders' Agreement for former profit
participating limited partners of The Goldman Sachs Group, L.P.
(incorporated by reference to Exhibit I to Amendment No. 2 to the
Initial Schedule 13D, filed June 21, 2000 (File No. 005-56295)).
C. Form of Counterpart to Shareholders' Agreement for non-U.S.
corporations (incorporated by reference to Exhibit L to Amendment
No. 3 to the Initial Schedule 13D, filed June 30, 2000 (File
No. 005-56295)).
D. Form of Counterpart to Shareholders' Agreement for non-U.S. trusts
(incorporated by reference to Exhibit M to Amendment No. 3 to the
Initial Schedule 13D, filed June 30, 2000 (File No. 005-56295)).
E. Supplemental Registration Rights Instrument, dated as of June 19, 2000
(incorporated by reference to Exhibit R to Amendment No. 5 to the
Initial Schedule 13D, filed August 2, 2000 (File No. 005-56295)).
F. Power of Attorney (incorporated by reference to Exhibit F to Amendment
No. 91 to the Initial Schedule 13D, filed February 9, 2016 (File
No. 005-56295)).
G. Form of Written Consent Relating to Sale and Purchase of Common Stock
(incorporated by reference to Exhibit FF to Amendment No. 35 to the
Initial Schedule 13D, filed January 8, 2003 (File No. 005-56295)).
H. Amended and Restated Shareholders' Agreement, effective as of
January 15, 2015 (incorporated by reference to Exhibit 10.6 to GS
Inc.'s Annual Report on Form 10-K for the fiscal year ended
December 31, 2014 (File No. 001-14965)).
-13-
ANNEX B
ITEM 5(A). DESCRIPTION OF SHARES AS TO WHICH THERE IS A RIGHT TO ACQUIRE
EXERCISABLE WITHIN 60 DAYS.
An aggregate of 2,006,931 shares of Common Stock are deliverable to Covered
Persons upon the exercise of stock options that have vested and are
exercisable. In addition, up to 70,734 shares of Common Stock are deliverable
pursuant to the terms of an equal number of restricted stock units, pending
satisfaction of certain conditions of delivery.
The share amounts given above include the gross number of shares of Common
Stock underlying these options and restricted stock units, and these shares are
included in the aggregate number of shares beneficially owned by the Covered
Persons under Rule 13d-3(d)(1) because they represent a right to acquire
beneficial ownership within 60 days of July 3, 2017. Upon exercise of stock
options or delivery of the shares pursuant to the terms of the restricted stock
units, a net amount of shares will be actually delivered to the Covered Person,
with some shares withheld for tax payments, to fund the option strike price or
for other reasons. The net shares delivered to the Covered Person will continue
to be included in the aggregate number of shares beneficially owned by the
Covered Persons. The withheld shares will cease to be beneficially owned by any
Covered Person, and will no longer be included in the aggregate number of
shares beneficially owned by Covered Persons.
Prior to delivery, the shares are included in Sixty Day Shares because the
Covered Persons do not have the right to vote the shares. Upon delivery, the
shares become Voting Shares.
-15-
ANNEX C
ITEM 5(C). DESCRIPTION OF ALL TRANSACTIONS IN THE COMMON STOCK EFFECTED BY
COVERED PERSONS IN THE PAST 60 DAYS AND NOT PREVIOUSLY REPORTED
ON SCHEDULE 13D.
The following sales of Voting Shares were made by the following Covered Persons
through one or more subsidiaries of GS Inc. for cash on the New York Stock
Exchange or by delivery to counterparties upon settlement of derivative
transactions:
* This transaction was conducted through an estate planning entity or private
charitable foundation and relates to Other Shares.
-16-
The following charitable contributions and other transfers of shares in
transactions for which no consideration was received were made by the following
Covered Persons:
Acquisition or
Covered Person Transfer Date Number of Shares Disposition
-------------- ------------- ---------------- --------------
Thomas C. Morrow May 10, 2017 1,115 Disposition
Andre Helmut Kelleners May 15, 2017 100 Disposition
-17-
ANNEX D
ITEM 6. DESCRIPTION OF POSITIONS IN DERIVATIVE INSTRUMENTS OF COVERED
PERSONS.
The following Covered Persons have written or purchased American-style
standardized call options or put options on Voting Shares. The following sets
forth the terms of options that were in place on July 3, 2017:
Strike
Instrument and Number of Price
Covered Person Position Shares (in $) Maturity Date
-------------- -------------- --------- ------ ------------------
Nicole Vijay Agnew Call Written 2,800 235 September 15, 2017
Gregory A. Agran Call Written 6,200 260 July 21, 2017
Gregory A. Agran Call Written 5,000 255 July 21, 2017
Denis P. Coleman III Call Written 3,900 240 October 20, 2017
Alessandro Dusi Call Written 1,500 230 October 20, 2017
Alessandro Dusi Call Written 1,000 220 October 20, 2017
Peter Gross Call Written 4,100 250 September 15, 2017
Laurent Lellouche Put Written 8,100 150 January 19, 2018
Gwen R. Libstag* Call Written 4,400 240 July 21, 2017
Gwen R. Libstag* Call Written 4,400 230 July 21, 2017
Gwen R. Libstag* Call Written 4,000 250 July 21, 2017
Gwen R. Libstag* Call Written 23,600 245 July 21, 2017
Gwen R. Libstag* Call Written 4,400 235 July 21, 2017
Ali S. Melli Call Written 2,000 265 July 21, 2017
Ali S. Melli Call Written 100 270 July 21, 2017
Ali S. Melli Call Written 2,000 260 July 21, 2017
Ganesh Ramani Call Written 7,300 260 January 19, 2018
Mahesh Saireddy Call Written 5,000 250 January 19, 2018
Michael H. Siegel Call Written 1,000 230 January 19, 2018
Kristin O. Smith Call Written 200 250 July 21, 2017
* This transaction was conducted through an estate planning entity or private
charitable foundation and relates to Other Shares.
-18-
EXHIBIT INDEX
Exhibit Description
------- ----------------------------------------------------------------------
A. Registration Rights Instrument, dated as of December 10, 1999
(incorporated by reference to Exhibit G to Amendment No. 1 to the
Initial Schedule 13D, filed December 17, 1999 (File No. 005-56295)).
B. Form of Counterpart to Shareholders' Agreement for former profit
participating limited partners of The Goldman Sachs Group, L.P.
(incorporated by reference to Exhibit I to Amendment No. 2 to the
Initial Schedule 13D, filed June 21, 2000 (File No. 005-56295)).
C. Form of Counterpart to Shareholders' Agreement for non-U.S.
corporations (incorporated by reference to Exhibit L to Amendment
No. 3 to the Initial Schedule 13D, filed June 30, 2000 (File
No. 005-56295)).
D. Form of Counterpart to Shareholders' Agreement for non-U.S. trusts
(incorporated by reference to Exhibit M to Amendment No. 3 to the
Initial Schedule 13D, filed June 30, 2000 (File No. 005-56295)).
E. Supplemental Registration Rights Instrument, dated as of June 19, 2000
(incorporated by reference to Exhibit R to Amendment No. 5 to the
Initial Schedule 13D, filed August 2, 2000 (File No. 005-56295)).
F. Power of Attorney (incorporated by reference to Exhibit F to Amendment
No. 91 to the Initial Schedule 13D, filed February 9, 2016 (File
No. 005-56295)).
G. Form of Written Consent Relating to Sale and Purchase of Common Stock
(incorporated by reference to Exhibit FF to Amendment No. 35 to the
Initial Schedule 13D, filed January 8, 2003 (File No. 005-56295)).
H. Amended and Restated Shareholders' Agreement, effective as of
January 15, 2015 (incorporated by reference to Exhibit 10.6 to GS
Inc.'s Annual Report on Form 10-K for the fiscal year ended
December 31, 2014 (File No. 001-14965)).